Optimizing molecular residual disease detection using liquid biopsy postoperatively in early stage lung cancer

Lung Cancer Manag. 2020 Feb 21;9(2):LMT24. doi: 10.2217/lmt-2019-0017.

Anna L McGuire¹, Curtis B Hughesman², Melissa K McConechy³, Barb Melosky^{4

5}, Stephen Lam^{4

6}, Renelle Myers^{4

6}, John Yee¹, Ernest Tang¹, Stephen Yip^{2

7}

¹ Department of Surgery, Division of Thoracic Surgery, Vancouver General Hospital, University of British Columbia, Vancouver V5Z1M9, BC, Canada.
² Department of Pathology and Laboratory Medicine, BC Cancer, Cancer Genetics & Genomics Laboratory, Vancouver, BC, Canada.
³ Contextual Genomics Inc., Vancouver, BC, Canada.
⁴ Department of Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Vancouver, BC, Canada.
⁵ Medical Oncology, University of British Columbia, Vancouver, BC, Canada.
⁶ Department of Medicine, Divisions of Respiratory Medicine, University of British Columbia, Vancouver, BC, Canada.
⁷ Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

No abstract available

Keywords: biomarkers; genetics; lung; lung cancer; molecular oncology; oncology; personalized medicine; surgery; surgical.

Publication types